Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06419205
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2024-05-08
Brief Title:
A Phase 2 Study to Evaluate the Safety PD PK and Clinical Activity of ADX-097 in Participants With IgAN LN or C3G
Sponsor:
Q32 Bio Inc
Organization:
Q32 Bio Inc
Study Overview
Official Title:
A Phase 2 Study to Evaluate the Safety Pharmacodynamics Pharmacokinetics and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With IgAN LN or C3G
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 2 Study to Evaluate the Safety Pharmacodynamics Pharmacokinetics and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With Immunoglobulin A Nephropathy IgAN Lupus Nephritis LN or Complement Component 3 Glomerulopathy C3G
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None